Journal Home
Search for

Volume 39, Issue 4, Pages 644-654 (April 2010)


View previous. 5 of 22 View next.

How Much Does It Cost a Specialist Palliative Care Unit to Manage Constipation in Patients Receiving Opioid Therapy?

Bee Wee, MB BCh, MRCGP, FRCP, MA Ed, PhDabcCorresponding Author Informationemail address, Astrid Adams, MBBS, BSc, Dip Pall Med, MRCPad, Kate Thompson, BN, PgD Advanced Nursing, MSca, Fran Percival, BPharm(Hons), MA, MRPharmSe, Kate Burslem, BSc(Hons), MScf, Minesh Jobanputra, MB ChBf

Accepted 28 September 2009. published online 12 March 2010.

Abstract 

The burden of constipation from the patient's perspective has been well described. The aim of this study was to evaluate the cost of managing constipation in patients taking opioids in a specialist palliative care inpatient unit. A retrospective review of the medical records of 58 patients (70 admissions) who died during a six-month period was undertaken to identify prescribing patterns for opioids and oral laxatives and tasks associated with managing constipation in these patients. A prospective time and motion study also was undertaken, whereby staff recorded the time and resources required to perform each task. These data were then applied to the actual frequency recorded in the retrospective review to calculate the direct cost of managing constipation in those 70 admissions during that six-month period. There was no discernable pattern in oral laxative prescribing. The mean cost of managing constipation was £29.81 (48.74 USD) per admission, with staff time accounting for 85% of the cost. The most time-consuming activity was staff discussion about bowel management, which occurred at least once daily for doctors and twice for nurses and involved up to eight members of staff at a time. The cost of managing constipation is skewed in that it costs £30 (49 USD) or less in 71% of admissions but exceeded £100 (163 USD) in 5%. In the latter group, earlier and/or more effective intervention for constipation could lead to clinical and economic benefits.

a Sir Michael Sobell House, Churchill Hospital, Oxford, United Kingdom

b Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom

c Harris Manchester College, Oxford University, Oxford, United Kingdom

d Oxford Deanery, Oxford, United Kingdom

e pH Associates, Marlow, United Kingdom

f Wyeth Pharmaceuticals, Taplow, United Kingdom

Corresponding Author InformationAddress correspondence to: Bee Wee, MB BCh, MRCGP, FRCP, MA Ed, PhD, Sir Michael Sobell House, Churchill Hospital, Oxford OX3 7LJ, United Kingdom.

 This study was carried out with the financial support of Wyeth Pharmaceuticals in the form of payment for pH Associates, an independent research organization, to perform data collection and analysis; and an honorarium to the host organization and research group at Sir Michael Sobell House where this study was undertaken.

PII: S0885-3924(10)00080-1

doi:10.1016/j.jpainsymman.2009.09.007


View previous. 5 of 22 View next.